INTERLEUKIN GENETICS INC
DelistedCIK 1037649fmd_14404CBN5562K741CEVP99S3BPManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2010 to Mar 31, 2017, 28 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 3 | 2 | 2 | 2 | 1 | 3 |
| Cost of revenue | 2 | 2 | 1 | 2 | 1 | 1 | 2 |
| Gross profit | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| Research and development | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation and amortization | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 6 | 5 | 4 | 7 | 6 | 6 | 6 |
| Total operating expenses | 7 | 6 | 6 | 7 | 7 | 7 | 8 |
| Operating income | (6) | 5 | (5) | (7) | (6) | (7) | (7) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (0) | (0) | (0) | (0) | (0) | (1) | (1) |
| Income before taxes | (6) | (5) | (5) | (7) | (6) | (8) | (7) |
| Income tax expense | – | 0 | 0 | 0 | 0 | – | – |
| Net income from continuing operations | (6) | (5) | (5) | (7) | (6) | – | – |
| Net income | (6) | (5) | 5 | 7 | 6 | 8 | 7 |